S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:KOOL

Cesca Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$2.32
-0.08 (-3.33 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.20
Now: $2.32
$2.45
50-Day Range
$2.11
MA: $2.78
$5.14
52-Week Range
$2.10
Now: $2.32
$7.00
Volume1.04 million shs
Average Volume112,188 shs
Market Capitalization$5.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.
Cesca Therapeutics logo

MarketRank

Overall MarketRank

1.12 out of 5 stars

Medical Sector

786th out of 1,556 stocks

Laboratory Apparatus & Furniture Industry

4th out of 5 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KOOL
CUSIPN/A
Phone916-858-5100
Employees53

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.67 million
Book Value$3.11 per share

Profitability

Net Income$-39,720,000.00

Miscellaneous

Market Cap$5.61 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KOOL News and Ratings via Email

Sign-up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions

What stocks does MarketBeat like better than Cesca Therapeutics?

Wall Street analysts have given Cesca Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cesca Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) issued its earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative return on equity of 77.30% and a negative net margin of 98.84%.
View Cesca Therapeutics' earnings history
.

Who are some of Cesca Therapeutics' key competitors?

What other stocks do shareholders of Cesca Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), NVIDIA (NVDA), QUALCOMM (QCOM), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD).

Who are Cesca Therapeutics' key executives?

Cesca Therapeutics' management team includes the following people:
  • Dr. Xiaochun Xu M.B.A., Ph.D., Chairman, CEO & Pres (Age 48)
  • Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 46)
  • Mr. James Xu J.D., L.L.M., M.B.A., Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec. (Age 48)
  • Mr. Philip H. Coelho, Chief Technology Officer (Age 75)
  • Ms. Haihong Zhu, Pres of ThermoGenesis

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

What is Cesca Therapeutics' stock price today?

One share of KOOL stock can currently be purchased for approximately $2.32.

How big of a company is Cesca Therapeutics?

Cesca Therapeutics has a market capitalization of $5.61 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe.

What is Cesca Therapeutics' official website?

The official website for Cesca Therapeutics is www.cescatherapeutics.com.

How can I contact Cesca Therapeutics?

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.